PROF Earnings Prediction
The chart below shows how PROF performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PROF sees a -0.65% change in stock price 10 days leading up to the earnings, and a -3.38% change 10 days following the report. On the earnings day itself, the stock moves by +1.33%. This data can give you a slight idea of what to expect for the next quarter's release.
PROF Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
2.83M
63.89%
26.82%
Gross Margin
63.77%
3.96%
-0.98%
Operating Margin
-317.37%
-16.40%
-9.52%
Net Margin
-330.65%
2.69%
6.71%
EPS
-0.38
-46.15%
35.71%
No Data Available
PROF Earnings Analysis
Profound Medical Corp. Common Stock Corporation (PROF.O) Earnings Conference Call
Positive
Revenue Breakdown Analysis: The company recorded revenue of $2.83 million with $2.65 million from recurring revenue and $179,000 from one-time sale of capital equipment.
Revenue Surge 64%: Third quarter 2024 revenue increased 64% from $1.73 million from the same period in 2023.
Gross Margin Improvement: Gross margin in Q3 2024 was 64% compared to 61% in Q3 2023.
Operating Expenses Increase: Total operating expenses in 2024 third quarter were $10.8 million, an increase of 42% compared to $7.6 million in the third quarter of 2023.
Cash Position Update: As of September 30, 2024, Profound had cash of $27.1 million.
Negative
Net Loss Comparison: The company recorded a net loss of $9.4 million or $0.38 per common share, compared to a net loss of $5.6 million or $0.26 per common share for the same period in 2023.
Operating Expenses Increase: Total operating expenses in 2024 third quarter were $10.8 million, an increase of 42% compared to $7.6 million in the third quarter of 2023.
Net Finance Expense Comparison: Net finance expense for the 2024 third quarter was $199,000 compared to net finance income of $1 million for the same three-month period of 2023.
R&D Expenditure Increase: R&D expenditures increased 22% on a year-over-year basis to $4.2 million.
Expense Increases Overview: G&A expenses increased by 84% to $3.7 million and sales and distribution expenses increased by 34% to $2.9 million.
PROF FAQs
How does PROF typically perform around its earnings report dates?
Is Profound Medical Corporation (PROF) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PROF Earning Call Sentiment
Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PROF.O
-1.09%Positive
The earnings call showed positive revenue growth and improved gross margins, but was offset by increased operating expenses and a higher net loss. The Q&A session revealed optimistic management on future growth and adoption, but lacked specific guidance on capital vs. recurring revenue, which could concern investors. No shareholder return plans were announced, and operational risks were noted. Overall, the sentiment is mixed, leading to a neutral prediction for stock movement.